📣 VC round data is live. Check it out!

COSMOS Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for COSMOS Pharmaceutical and similar public comparables like DaShenLin Pharmaceutical, Sundrug, Fragua, Sugi Holdings and more.

COSMOS Pharmaceutical Overview

About COSMOS Pharmaceutical

COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company’s revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.


Founded

1983

HQ

Japan

Employees

28.8K

Sectors

Financials (LTM)

Revenue: $7B
EBITDA: $423M

EV

$3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

COSMOS Pharmaceutical Financials

COSMOS Pharmaceutical reported last 12-month revenue of $7B and EBITDA of $423M.

In the same LTM period, COSMOS Pharmaceutical generated $1B in gross profit, $423M in EBITDA, and $203M in net income.

Revenue (LTM)


COSMOS Pharmaceutical P&L

In the most recent fiscal year, COSMOS Pharmaceutical reported revenue of $7B and EBITDA of $423M.

COSMOS Pharmaceutical is profitable as of last fiscal year, with gross margin of 20%, EBITDA margin of 6%, and net margin of 3%.

See analyst estimates for COSMOS Pharmaceutical
LTMLast FY202320242025202620272028
Revenue$7B$7B$6B$6B$7B
Gross Profit$1B$1B$1B$1B$1B
Gross Margin21%20%20%20%21%
EBITDA$423M$423M$333M$383M$419M
EBITDA Margin6%6%6%6%6%
EBIT Margin4%4%3%4%4%
Net Profit$203M$210M$154M$180M$200M
Net Margin3%3%3%3%3%

Financial data powered by Morningstar, Inc.

COSMOS Pharmaceutical Stock Performance

COSMOS Pharmaceutical has current market cap of $3B, and enterprise value of $3B.

Market Cap Evolution


COSMOS Pharmaceutical's stock price is $39.27.

COSMOS Pharmaceutical share price increased by 4.1% in the last 30 days, and decreased by 29.4% in the last year.

COSMOS Pharmaceutical has an EPS (earnings per share) of $2.65.

See more trading valuation data for COSMOS Pharmaceutical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3B$3B-0.1%4.1%-10.1%-29.4%$2.65

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

COSMOS Pharmaceutical Valuation Multiples

COSMOS Pharmaceutical trades at 0.5x EV/Revenue multiple, and 7.7x EV/EBITDA.

See NTM and 2027E valuation multiples for COSMOS Pharmaceutical

EV / Revenue (LTM)


COSMOS Pharmaceutical Financial Valuation Multiples

As of May 3, 2026, COSMOS Pharmaceutical has market cap of $3B and EV of $3B.

COSMOS Pharmaceutical has a P/E ratio of 15.3x.

LTMLast FY202320242025202620272028
EV/Revenue0.5x0.5x0.6x0.5x0.5x
EV/EBITDA7.7x7.7x9.7x8.4x7.7x
EV/EBIT12.1x11.8x16.4x13.9x12.3x
EV/Gross Profit2.2x2.4x2.8x2.5x2.3x
P/E15.3x14.8x20.2x17.3x15.5x
EV/FCF70.9xn/m176.7xn/m119.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified COSMOS Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

COSMOS Pharmaceutical Margins & Growth Rates

COSMOS Pharmaceutical grew revenue by 2% and EBITDA by 0% in the last fiscal year.

In the most recent fiscal year, COSMOS Pharmaceutical reported gross margin of 20%, EBITDA margin of 6%, and net margin of 3%.

See estimated margins and future growth rates for COSMOS Pharmaceutical

COSMOS Pharmaceutical Margins

Last FY202420252026202720282029
Gross Margin20%20%21%21%
EBITDA Margin6%6%6%6%
EBIT Margin4%4%4%4%
Net Margin3%3%3%3%
FCF Margin(0%)(0%)0%1%

COSMOS Pharmaceutical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth2%9%7%8%
Gross Profit Growth8%13%10%8%
EBITDA Growth0%15%9%5%
EBIT Growth(3%)19%13%5%
Net Profit Growth(3%)17%11%4%
FCF Growth(1023%)(127%)(657%)88%

Data powered by FactSet, Inc. and Morningstar, Inc.

COSMOS Pharmaceutical Operational KPIs

COSMOS Pharmaceutical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.

COSMOS Pharmaceutical's Rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

COSMOS Pharmaceutical's Rule of X is 25% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for COSMOS Pharmaceutical
LTMLast FY202320242025202620272028
Rule of 4013%14%
Bessemer Rule of X24%25%
Revenue per Employee$0.2M
Opex per Employee$0.0M
S&M Expenses to Revenue0%0%0%0%
Opex to Revenue16%16%17%16%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

COSMOS Pharmaceutical Competitors

COSMOS Pharmaceutical competitors include DaShenLin Pharmaceutical, Sundrug, Fragua, Sugi Holdings, Nahdi Medical, Ebos Group, Clicks Group, Jointown Pharmaceutical, Kusuri No Aoki and Yifeng Pharmacy.

Most COSMOS Pharmaceutical public comparables operate across Pharmacies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
DaShenLin Pharmaceutical0.7x0.7x5.4x5.5x
Sundrug0.5x0.5x6.3x6.3x
Fragua0.4x0.3x7.0x4.4x
Sugi Holdings0.6x0.5x9.7x7.9x
Nahdi Medical1.5x1.4x8.6x8.5x
Ebos Group0.5x0.4x9.7x8.4x
Clicks Group1.3x1.2x9.3x9.0x
Jointown Pharmaceutical0.2x0.2x5.3x5.7x

This data is available for Pro users. Sign up to see all COSMOS Pharmaceutical competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About COSMOS Pharmaceutical

When was COSMOS Pharmaceutical founded?COSMOS Pharmaceutical was founded in 1983.
Where is COSMOS Pharmaceutical headquartered?COSMOS Pharmaceutical is headquartered in Japan.
How many employees does COSMOS Pharmaceutical have?As of today, COSMOS Pharmaceutical has over 28K employees.
Is COSMOS Pharmaceutical publicly listed?Yes, COSMOS Pharmaceutical is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of COSMOS Pharmaceutical?COSMOS Pharmaceutical trades under 3349 ticker.
When did COSMOS Pharmaceutical go public?COSMOS Pharmaceutical went public in 2004.
Who are competitors of COSMOS Pharmaceutical?COSMOS Pharmaceutical main competitors include DaShenLin Pharmaceutical, Sundrug, Fragua, Sugi Holdings, Nahdi Medical, Ebos Group, Clicks Group, Jointown Pharmaceutical, Kusuri No Aoki, Yifeng Pharmacy.
What is the current market cap of COSMOS Pharmaceutical?COSMOS Pharmaceutical's current market cap is $3B.
What is the current revenue of COSMOS Pharmaceutical?COSMOS Pharmaceutical's last 12 months revenue is $7B.
What is the current revenue growth of COSMOS Pharmaceutical?COSMOS Pharmaceutical revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of COSMOS Pharmaceutical?Current revenue multiple of COSMOS Pharmaceutical is 0.5x.
Is COSMOS Pharmaceutical profitable?Yes, COSMOS Pharmaceutical is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of COSMOS Pharmaceutical?COSMOS Pharmaceutical's last 12 months EBITDA is $423M.
What is COSMOS Pharmaceutical's EBITDA margin?COSMOS Pharmaceutical's last 12 months EBITDA margin is 6%.
What is the current EV/EBITDA multiple of COSMOS Pharmaceutical?Current EBITDA multiple of COSMOS Pharmaceutical is 7.7x.
What is the current FCF of COSMOS Pharmaceutical?COSMOS Pharmaceutical's last 12 months FCF is $46M.
What is COSMOS Pharmaceutical's FCF margin?COSMOS Pharmaceutical's last 12 months FCF margin is 1%.
What is the current EV/FCF multiple of COSMOS Pharmaceutical?Current FCF multiple of COSMOS Pharmaceutical is 70.9x.
How many companies COSMOS Pharmaceutical has acquired to date?COSMOS Pharmaceutical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies COSMOS Pharmaceutical has invested to date?COSMOS Pharmaceutical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to COSMOS Pharmaceutical

Lists including COSMOS Pharmaceutical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial